First Oral Treatment Option for Non-Hospitalized COVID-19 patients Studied in Phase 2

Switzerland-based Roche and Atea Pharmaceuticals, Inc. announced that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to people around the globe. 

AT-527 is an investigational, oral, purine nucleotide prodrug, which has demonstrated in vitro and in vivo antiviral activity against several enveloped single-stranded RNA viruses and is currently being studied in a Phase 2 clinical trial for hospitalized patients with moderate COVID-19.

In addition, AT-527 may be developed for post-exposure prophylactic settings.